Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trialKirsten E. Lyke, William Edward Witt, Azza H. Idris et al.|The Lancet Infectious Diseases|2023Cited by 42
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccineJoseph P. Casazza, Amelia R. Hofstetter, Pamela Costner et al.|npj Vaccines|2024Cited by 22